Johnson & Johnson (JNJ) Receives $142.41 Consensus Target Price from Analysts
Johnson & Johnson (NYSE:JNJ) has received an average recommendation of “Hold” from the twenty-three ratings firms that are presently covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $142.41.
Several equities research analysts have issued reports on the company. ValuEngine downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b” rating in a research report on Friday, May 18th. Credit Suisse Group set a $151.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 target price on Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Finally, Deutsche Bank restated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 18th.
Several hedge funds have recently modified their holdings of JNJ. BlackRock Inc. raised its position in shares of Johnson & Johnson by 4.7% in the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after buying an additional 7,853,141 shares in the last quarter. Boston Partners raised its position in shares of Johnson & Johnson by 68.7% in the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock worth $1,638,258,000 after buying an additional 5,207,124 shares in the last quarter. Charles Schwab Investment Advisory Inc. purchased a new stake in shares of Johnson & Johnson in the second quarter worth $383,285,000. Cornerstone Wealth Management LLC raised its position in shares of Johnson & Johnson by 10,307.6% in the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock worth $20,537,000 after buying an additional 2,473,105 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Johnson & Johnson by 36.1% in the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock worth $838,515,000 after buying an additional 1,833,622 shares in the last quarter. Institutional investors own 66.22% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.06 by $0.04. The firm had revenue of $20.83 billion for the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The business’s quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.83 earnings per share. equities research analysts forecast that Johnson & Johnson will post 8.14 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th will be given a $0.90 dividend. The ex-dividend date is Monday, August 27th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.75%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Marijuana Stocks Investing Considerations
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.